目的 系统评价连花清瘟（胶囊/颗粒）治疗流行性感冒的疗效及安全性，为临床用药提供循证医学支持。方法 计算机检索PubMed、Web of Science、Embase、Cochrane Library、中国知网（CNKI）、维普（VIP）、万方（Wanfang Data）、中国生物医学文献（CBM）数据库，时间截止至2020年11月10日，搜索连花清瘟（试验组）对比化学药及其他中成药（对照组）治疗流行性感冒的临床随机对照试验（randomized controlled trial，RCT）。根据Cochrane标准筛选纳入研究，提取数据并运用RevMan5.4、Stata14.0软件进行Meta分析。结果 共计纳入19篇文献，涉及2651例流行性感冒患者，分析结果显示，与对照组相比，试验组可提高患者临床总有效率[OR=3.18，95% CI（2.54，3.97），P<0.000 01]；有效缩短发热时间[SMD=-0.77，95% CI（-1.15，-0.39），P<0.000 1]、咽痛症状缓解时间[MD=-8.66，95% CI（-12.42，-4.90），P<0.000 01]、全身酸痛缓解时间[MD=-27.87，95% CI（-50.65，-5.09），P=0.02]；在咳嗽症状缓解时间方面[MD=-8.07，95% CI（-16.05，-0.08），P=0.05]，2组差异具有统计学意义；在病毒核酸转阴时间方面[MD=1.39，95% CI（-7.24，10.02），P=0.75]，2组差异无统计学意义。结论 连花清瘟对流行性感冒患者临床症状的改善具有一定的疗效和安全性。

Objective To evaluate the efficacy of Lianhua Qingwen Capsule/Granule (连花清瘟胶囊/颗粒) in treatment of influenza, and provide evidence-based medical basis for clinical medication.Methods Eight databases (PubMed, Web of Science, Embase, Cochrane Library, CNKI, VIP, Wanfang Data and CBM) were searched up to November 10, 2020. Randomized controlled trials (RCT) was conducted on Lianhua Qingwen (experimental group) in the treatment of influenza by comparing chemical drugs and other Chinese patent medicines (control group). All included studies were critically appraised according to the cochrane systematic review method and using Revman 5.4 Software and Stata 14.0 for Meta-analysis. Results Nineteen RCTs with 2651 patients were included. This Meta-analysis showed that compared with control group, Lianhua Qingwen significantly improved the effective rate of clinical symptoms[OR=3.18, 95% CI (2.54, 3.97), P < 0.000 01], and effectively shorten the heating time[SMD=-0.77, 95% CI (-1.15, -0.39), P < 0.000 1], the relief time of sore throat[MD=-8.66, 95% CI (-12.42, -4.90), P < 0.000 01], the relief time of body ache[MD=-27.87, 95% CI (-50.65, -5.09), P=0.02]. The difference between the two groups was statistically significant in the relief time of cough symptoms[MD=-8.07, 95% CI (-16.05, -0.08), P=0.05]. There was no significant difference between the two groups in the time of viral nucleic acid turning negative[MD=1.39, 95% CI (-7.24, 10.02), P=0.75]. Conclusion Lianhua Qingwen can effectively improve the clinical symptoms of influenza patients.

R285.64

基于优化后中医诊疗方案的慢性阻塞性肺疾病前瞻性队列研究（2020SF-351）；国家中医药管理局医史文献重点学科建设单位（国中医药发[2009]30号）；陕西省感染性疾病临床医学研究中心（中西医结合）项目（2020LCZX-02）